Reversal of Tau-Dependent Cognitive Decay by Blocking Adenosine A1 Receptors: Comparison of Transgenic Mouse Models with Different Levels of Tauopathy

The accumulation of tau is a hallmark of several neurodegenerative diseases and is associated with neuronal hypoactivity and presynaptic dysfunction. Oral administration of the adenosine A1 receptor antagonist rolofylline (KW-3902) has previously been shown to reverse spatial memory deficits and to normalize the basic synaptic transmission in a mouse line expressing full-length pro-aggregant tau (TauΔK) at low levels, with late onset of disease. However, the efficacy of treatment remained to be explored for cases of more aggressive tauopathy. Using a combination of behavioral assays, imaging with several PET-tracers, and analysis of brain tissue, we compared the curative reversal of tau pathology by blocking adenosine A1 receptors in three mouse models expressing different types and levels of tau and tau mutants. We show through positron emission tomography using the tracer [18F]CPFPX (a selective A1 receptor ligand) that intravenous injection of rolofylline effectively blocks A1 receptors in the brain. Moreover, when administered to TauΔK mice, rolofylline can reverse tau pathology and synaptic decay. The beneficial effects are also observed in a line with more aggressive tau pathology, expressing the amyloidogenic repeat domain of tau (TauRDΔK) with higher aggregation propensity. Both models develop a progressive tau pathology with missorting, phosphorylation, accumulation of tau, loss of synapses, and cognitive decline. TauRDΔK causes pronounced neurofibrillary tangle assembly concomitant with neuronal death, whereas TauΔK accumulates only to tau pretangles without overt neuronal loss. A third model tested, the rTg4510 line, has a high expression of mutant TauP301L and hence a very aggressive phenotype starting at ~3 months of age. This line failed to reverse pathology upon rolofylline treatment, consistent with a higher accumulation of tau-specific PET tracers and inflammation. In conclusion, blocking adenosine A1 receptors by rolofylline can reverse pathology if the pathological potential of tau remains below a threshold value that depends on concentration and aggregation propensity.

[1]  Joanne Baltos,et al.  Adenosine receptor signalling in Alzheimer’s disease , 2022, Purinergic Signalling.

[2]  O. Piguet,et al.  Olfactory Bulb Integrity in Frontotemporal Dementia and Alzheimer's Disease. , 2022, Journal of Alzheimer's disease : JAD.

[3]  D. Geschwind,et al.  Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration , 2022, Cell.

[4]  B. Bardoni,et al.  Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders , 2021, Molecular Psychiatry.

[5]  D. Attwell,et al.  Brain’s immune cells put the brakes on neurons , 2020, Nature.

[6]  Ukpong B. Eyo,et al.  Negative feedback control of neuronal activity by microglia , 2020, Nature.

[7]  K. Ashe,et al.  Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice , 2019, Nature Communications.

[8]  Y. Bouter,et al.  18F-FDG-PET in Mouse Models of Alzheimer's Disease , 2019, Front. Med..

[9]  E. Mandelkow,et al.  Screening of a neuronal cell model of tau pathology for therapeutic compounds , 2019, Neurobiology of Aging.

[10]  C. Murphy Olfactory and other sensory impairments in Alzheimer disease , 2018, Nature Reviews Neurology.

[11]  E. Sigurdsson,et al.  Tau-targeting therapies for Alzheimer disease , 2018, Nature Reviews Neurology.

[12]  P. Verstreken,et al.  Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau , 2018, Neuron.

[13]  E. Mandelkow,et al.  Anti-aggregant tau mutant promotes neurogenesis , 2017, Molecular Neurodegeneration.

[14]  Christoforos Hadjichrysanthou,et al.  Why do so many clinical trials of therapies for Alzheimer's disease fail? , 2017, The Lancet.

[15]  A. Blockeel,et al.  Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy , 2017, Alzheimer's Research & Therapy.

[16]  F. Cayabyab,et al.  Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration , 2017, Molecules.

[17]  A. Giralt,et al.  Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity , 2016, Neurobiology of Disease.

[18]  E. Mandelkow,et al.  Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280 , 2016, Proceedings of the National Academy of Sciences.

[19]  E. Mandelkow,et al.  Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau , 2015, Acta neuropathologica communications.

[20]  M. Frotscher,et al.  Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca++ dysregulation , 2015, Acta neuropathologica communications.

[21]  Bradley T. Hyman,et al.  The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease , 2014, Neuron.

[22]  C. Harrington,et al.  Tau-aggregation inhibitor therapy for Alzheimer's disease. , 2014, Biochemical pharmacology.

[23]  A. Giralt,et al.  Prostaglandin E2 EP1 Receptor Antagonist Improves Motor Deficits and Rescues Memory Decline in R6/1 Mouse Model of Huntington's Disease , 2014, Molecular Neurobiology.

[24]  K. Jellinger,et al.  Olfactory bulb involvement in neurodegenerative diseases , 2014, Acta Neuropathologica.

[25]  J. Kuret,et al.  Structural Determinants of Tau Aggregation Inhibitor Potency* , 2013, The Journal of Biological Chemistry.

[26]  E. Mandelkow,et al.  Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology , 2013, The FEBS journal.

[27]  E. Mandelkow,et al.  Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors , 2013, Neurobiology of Aging.

[28]  E. Mandelkow,et al.  Biochemistry and cell biology of tau protein in neurofibrillary degeneration. , 2012, Cold Spring Harbor perspectives in medicine.

[29]  I. Pérez-Otaño,et al.  Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease , 2012, Hippocampus.

[30]  R. D'Hooge,et al.  Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau , 2012, Acta Neuropathologica.

[31]  F. van Leuven,et al.  Early Improved and Late Defective Cognition Is Reflected by Dendritic Spines in Tau.P301L Mice , 2011, The Journal of Neuroscience.

[32]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[33]  R. D'Hooge,et al.  Reversibility of Tau-Related Cognitive Defects in a Regulatable FTD Mouse Model , 2011, Journal of Molecular Neuroscience.

[34]  Weifeng Xu,et al.  PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity , 2011, Current Opinion in Neurobiology.

[35]  Rudi D'Hooge,et al.  Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant , 2011, The Journal of Neuroscience.

[36]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[37]  B. Hocher,et al.  Adenosine A1 receptor antagonists in clinical research and development. , 2010, Kidney international.

[38]  Hsiao-Wen Chen,et al.  The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. , 2009, Human molecular genetics.

[39]  T. Ma,et al.  Synaptic Activity Reduces Intraneuronal Aβ, Promotes APP Transport to Synapses, and Protects against Aβ-Related Synaptic Alterations , 2009, The Journal of Neuroscience.

[40]  Stephen M. Smith,et al.  Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference , 2009, NeuroImage.

[41]  L. Costantini,et al.  Hypometabolism as a therapeutic target in Alzheimer's disease , 2008, BMC Neuroscience.

[42]  H. Bujard,et al.  The Potential for β-Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy , 2008, The Journal of Neuroscience.

[43]  Ping Huang,et al.  Metabolic control of proteasome function. , 2007, Physiology.

[44]  Hermann Bujard,et al.  The β-Propensity of Tau Determines Aggregation and Synaptic Loss in Inducible Mouse Models of Tauopathy* , 2007, Journal of Biological Chemistry.

[45]  S. Santi,et al.  Early detection of Alzheimer’s disease using neuroimaging , 2007, Experimental Gerontology.

[46]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[47]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[48]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[49]  R. D'Hooge,et al.  Neurocognitive and Psychotiform Behavioral Alterations and Enhanced Hippocampal Long-Term Potentiation in Transgenic Mice Displaying Neuropathological Features of Human α-Mannosidosis , 2005, The Journal of Neuroscience.

[50]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[51]  O. Vitolo,et al.  Dendrite and dendritic spine alterations in alzheimer models , 2004, Journal of neurocytology.

[52]  K. Herholz,et al.  Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[53]  Y. Dudai The neurobiology of consolidations, or, how stable is the engram? , 2004, Annual review of psychology.

[54]  F. LaFerla,et al.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.

[55]  Horst Halling,et al.  Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  Karl Zilles,et al.  In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography , 2003, NeuroImage.

[57]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[58]  J. Hardy,et al.  The relationship between amyloid and tau , 2003, Journal of Molecular Neuroscience.

[59]  Gary K. Beauchamp,et al.  Food Intake, Water Intake, and Drinking Spout Side Preference of 28 Mouse Strains , 2002, Behavior genetics.

[60]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[61]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Buccafusco Methods of Behavior Analysis in Neuroscience , 2000 .

[63]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[64]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  E. Mandelkow,et al.  Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Y. Sekino,et al.  Cellular localization of adenosine A1 receptors in rat forebrain: Immunohistochemical analysis using adenosine A1 receptor‐specific monoclonal antibody , 1999, The Journal of comparative neurology.

[67]  E. Kandel,et al.  Control of Memory Formation Through Regulated Expression of a CaMKII Transgene , 1996, Science.

[68]  H. Kase,et al.  KW‐3902, a selective high affinity antagonist for adenosine A1 receptors , 1996, British journal of pharmacology.

[69]  B. Gähwiler,et al.  Comparison of the actions of adenosine at pre‐ and postsynaptic receptors in the rat hippocampus in vitro. , 1992, The Journal of physiology.

[70]  R. Morris Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[71]  B. Reisberg,et al.  Regional correlation of PET and CT in senile dementia of the Alzheimer type. , 1983, AJNR. American journal of neuroradiology.

[72]  Edmund M. Glaser,et al.  Analysis of thick brain sections by obverse—Reverse computer microscopy: Application of a new, high clarity Golgi—Nissl stain , 1981, Journal of Neuroscience Methods.

[73]  J. Götz,et al.  Experimental Models of Tauopathy - From Mechanisms to Therapies. , 2019, Advances in experimental medicine and biology.

[74]  R. D'Hooge,et al.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy , 2016, Molecular Psychiatry.

[75]  A. Takashima Tauopathies and tau oligomers. , 2013, Journal of Alzheimer's disease : JAD.

[76]  Carlo Caltagirone,et al.  A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[77]  D. Holtzman,et al.  Deciphering Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[78]  K. Browman,et al.  Cued and Contextual Fear Conditioning for Rodents , 2009 .

[79]  T. Abel,et al.  Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. , 2008, Progress in brain research.

[80]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .

[81]  JoVE Video Dataset , 2022 .